Amyris Inc (OTCPK:AMRSQ)

$ 0.002 0 (0%) Market Cap: 745,000.00 Enterprise Value: - PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q1 2023 Amyris Inc Earnings Call Transcript
May 09, 2023

$0.79 (+1.96%)

Earnings
Q4 2022 Amyris Inc Earnings Call Transcript
Mar 15, 2023

$1.19 (-4.03%)

Earnings
Amyris Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Amyris Inc Earnings Call Transcript
Nov 08, 2022

$2.59 (+0.39%)

Earnings
Amyris Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 10, 2022
Q2 2022 Amyris Inc Earnings Call Transcript
Aug 09, 2022

$2.29 (-1.29%)

Earnings
Amyris Inc at Oppenheimer Consumer Growth and E-Commerce Conference (Virtual) Transcript
Jun 14, 2022
Amyris Inc at UBS Global Healthcare Conference Transcript
May 25, 2022
Amyris Inc at Cowen Future of the Consumer: Sustainable Growth for a New Ecosystem Conference Transcript
May 24, 2022
Amyris Inc at Morgan Stanley Sustainable Futures Conference (Virtual) Transcript
May 23, 2022
Q1 2022 Amyris Inc Earnings Call Transcript
May 10, 2022

$1.73 (-32.95%)

Earnings
Q4 2021 Amyris Inc Earnings Call Transcript
Mar 01, 2022

$4.77 (+4.61%)

Earnings
Amyris Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Amyris Inc Financing Activity Call Transcript
Nov 22, 2021
Q3 2021 Amyris Inc Earnings Call Transcript
Nov 08, 2021

$12.98 (-7.88%)

Earnings
Amyris Inc Fourth Virtual Investor Mini-Series Webinar Transcript
Sep 28, 2021
Amyris Inc at Oppenheimer Technology, Internet & Communications Conference (Virtual) Transcript
Aug 10, 2021
Q2 2021 Amyris Inc Earnings Call Transcript
Aug 05, 2021

$14.46 (+2.19%)

Earnings
Amyris Inc at Jefferies Consumer Conference (Virtual) Transcript
Jun 23, 2021
Amyris Inc at Morgan Stanley Sustainable Futures Conference (Virtual) Transcript
Jun 09, 2021
Amyris Inc at Morgan Stanley Global Ingredients Conference (Virtual) Transcript
May 18, 2021
Q1 2021 Amyris Inc Earnings Call Transcript
May 06, 2021

$11.41 (-16.16%)

Earnings
Amyris Inc Third Virtual Investor Mini-Series Webinar Transcript
Apr 22, 2021
Q4 2020 Amyris Inc Earnings Call Transcript
Mar 02, 2021

$19.95 (+27.39%)

Earnings
Amyris Inc Second Virtual Investor Mini-Series Webinar Transcript
Feb 09, 2021
Amyris Inc Science and Technology, Sustainable Solutions for a Healthier Planet Conference Call Transcript
Dec 15, 2020
Q3 2020 Amyris Inc Earnings Call Transcript
Nov 05, 2020

$2.13 (-19.01%)

Earnings
Q2 2020 Amyris Inc Earnings Call Transcript
Aug 06, 2020

$4.04 (-18.32%)

Earnings
Q1 2020 Amyris Inc Earnings Call Transcript
May 08, 2020

$2.68 (+6.35%)

Earnings
Q4 2019 Amyris Inc Earnings Call Transcript
Mar 12, 2020

$2.66 (-10.14%)

Earnings
Q3 2019 Amyris Inc Earnings Call Transcript
Nov 07, 2019

$3.98 (+0.51%)

Earnings
Q2 2019 Amyris Inc Earnings Call Transcript
Oct 02, 2019

$4.57 (-2.56%)

Earnings
Amyris Inc to Host Business Update Conference Call Transcript
Aug 05, 2019
Amyris Inc BioDisrupt 2019 Transcript
May 16, 2019
Amyris Inc at ROTH Conference Transcript
Mar 19, 2019
Q4 2018 Amyris Inc Earnings Call Transcript
Mar 18, 2019

Earnings

Amyris Inc at Jefferies Consumer Conference (Virtual) Transcript

Jun 23, 2021 / 07:15PM GMT

Release Date Price: $16.68 (+4.64%)

Transcript

Edlain Rodriguez

Jefferies Financial Group Inc. - Analyst

Okay. Thank you, guys, for joining us and welcome to the Amyris fireside chat with President and CEO, John Melo. I am Edlain Rodriguez from the Jefferies chemicals team. So without further ado, let's get started.

So, John, Amyris has one of the longest histories in synthetic biology, and you are flagged being capable of producing more than 250 molecules from 15 chemical families and over 20 biological pathways. But how would you differentiate Amyris' core approach from companies such as DSM, Genematics, Ginkgo? Like, what are the trade-offs for vertical integration all the way to the consumer brands?

John Melo

Amyris, Inc. - Director, President & CEO

Great. First of all, Edlain, very nice to be on this with you, and appreciate the invitation. Look, I'd say it's interesting, the names of the companies you just chose. Because I think some of them are academic, talking about a vision they haven't yet executed. And others are really significant, fantastic at synthetic biology and really very

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.